Cited by 79Retinal Development and DisordersRetinal Diseases and TreatmentsNeuroscience and Neural Engineering

Bioengineering strategies for restoring vision

Cehajic-Kapetanovic, Jasmina, Singh, Mandeep S., Zrenner, Eberhart, MacLaren, Robert E.·2022·Nature Biomedical Engineering

Abstract

Late-stage retinal degenerative disease involving photoreceptor loss can be treated by optogenetic therapy, cell transplantation and retinal prostheses. These approaches aim to restore light sensitivity to the retina as well as visual perception by integrating neuronal responses for transmission to the cortex. In age-related macular degeneration, some cell-based therapies also aim to restore photoreceptor-supporting tissue to prevent complete photoreceptor loss. In the earlier stages of degeneration, gene-replacement therapy could attenuate retinal-disease progression and reverse loss of function. And gene-editing strategies aim to correct the underlying genetic defects. In this Review, we highlight the most promising gene therapies, cell therapies and retinal prostheses for the treatment of retinal disease, discuss the benefits and drawbacks of each treatment strategy and the factors influencing whether functional tissue is reconstructed and repaired or replaced with an electronic device, and summarize upcoming technologies for enhancing the restoration of vision.

Integrity signals

Registry

Crossref · 10.1038/s41551-021-00836-4

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prospective approaches such as gene and cell therapies or optogenetics only focus on the retina and are ineffective when pathologies irremediably damage the retina or the optic nerve.

    “Prospective approaches, like gene and cell therapies or optogenetics, only focus on the retina [5,6], and they are ineffective when pathologies irremediably damage the retina or the optic nerve [7,8].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E.
Affiliations
  • Johns Hopkins University (US)
  • University of Tübingen (DE)
  • University of Oxford (GB)
Venue
Nature Biomedical Engineering
Published
2022-01-31
Volume
7
Issue
4
Pages
387-404
ISSN
2157-846X (ISSN-L)
OpenAlex
W4210615010
Cited by
79
References
207
Citations by year
2026: 8 · 2025: 24 · 2024: 19 · 2023: 19 · 2022: 9
FWCI
1.85
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
Funders
Oxford Biomedical Research Centre.
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neural Engineering
Keywords
vision restoration, retinal degeneration, photoreceptor loss, optogenetic therapy, cell transplantation, retinal prosthesis, age-related macular degeneration, gene therapy, genome editing, visual perception
MeSH terms
Humans, Retina, Retinal Degeneration, Vision, Ocular, Cell Transplantation, Bioengineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review